10x Insights
Loading account…
Companies / Healthcare / IRADIMED CORP
IRMD

IRADIMED CORP

HealthcareSurgical & Medical Instruments
Ticker IRMDORLANDO, FLFiscal year ends DecemberBook value per share $7.91Diluted shares 12.9M

IRADIMED Corporation (Nasdaq: IRMD) develops, manufactures, markets and distributes magnetic resonance imaging compatible medical devices and related accessories, disposables and services. The company is the only known provider of a non-magnetic intravenous infusion pump system specifically designed for safe use… From the company’s description.

Fiscal year 2025 · ends 12-31Changes are against fiscal 2024The amber dot is the latest twelve months, to 2026-06-30
Sales & profitability
$83.81M
+14.4% year over year
Last 12 mo $86.34M
31.20%
+1.2 percentage points
Last 12 mo 31.91%
$22.48M
+16.9% year over year
Last 12 mo $23.05M
23.76%
+1.6 percentage points
Last 12 mo 22.66%
Cash & financing
$24.95M
−2.6% year over year
Last 12 mo $27.14M
$16.53M
−1.7% year over year
Last 12 mo $24.87M
—
12.9M
+0.6% year over year
Last 12 mo 12.9M

Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.

What IRADIMED CORP does

In the company’s own words

IRADIMED Corporation (Nasdaq: IRMD) develops, manufactures, markets and distributes magnetic resonance imaging compatible medical devices and related accessories, disposables and services. The company is the only known provider of a non-magnetic intravenous infusion pump system specifically designed for safe use during MRI procedures, operating dependably in magnetic fields up to 15,000 gauss.

The company's primary product portfolio consists of four main offerings. The MRidium 3870 MRI Compatible IV Infusion Pump System, introduced in 2025, features a non-magnetic ultrasonic motor and touch screen interface designed to safely deliver anesthesia and critical care IV fluids during MRI procedures. The MRidium 3860+ IV Infusion Pump System, introduced in 2009, represents the company's second-generation infusion pump technology. The IRadimed 3880 MRI Compatible Patient Vital Signs Monitoring System operates in magnetic fields up to 30,000 gauss and provides wireless ECG, blood oxygen saturation monitoring, and blood pressure capabilities. The company also offers the IRadimed FMD1 3600 ferromagnetic detection device with remote alarm logging capabilities, introduced in 2022.

As of December 31, 2025, the company had sold approximately 13,098 MRI compatible IV infusion pump system channels and approximately 3,397 of its 3880 vital signs monitoring systems. The company employs a direct sales strategy in the United States with 29 field sales representatives, 4 regional sales directors, and 10 clinical application specialists. Internationally, products are marketed through independent distributors in approximately 80 countries.

In fiscal year 2025, the company generated revenue of $83.8 million with operating income of $26.1 million, representing an operating profit margin of approximately 31.2 percent. The company sells primarily to hospitals and acute care facilities. The business model generates revenue from device sales, extended maintenance agreements, service contracts, and disposable products used with its devices. The company was originally incorporated in Oklahoma in 1992 and reincorporated in Delaware in 2014.

Company details
Sector
Healthcare
Industry
Surgical & Medical Instruments
Headquarters
ORLANDO, FL
Fiscal year end
December
CIK
1325618
SIC
3841

Financial performance, year by year

Fiscal 2014–2025 · USD
$-8.63M$17.27M$43.17M$69.07M$94.97M201420152016201720182019202020212022202320242025Last 12 moLast 12 monthsLast 12 months

The full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.

Ownership

Who owns IRADIMED CORP — and what changed

Funds as of 2026Q2 · superinvestors as of 2026-06-30

224
funds hold it
0 of 35
superinvestors hold it
$252.80M
held by funds, at market
21.6%
of shares held by funds

Largest fund holders · IRADIMED CORP’s weight in each

VANGUARD TOTAL STOCK MARKET INDEX FUND
VTI · VANGUARD INDEX FUNDS
0.00%of fund net assets
iShares Russell 2000 ETF
IWM · iShares Trust
0.02%of fund net assets
Virtus KAR Small-Cap Growth Fund
PSGAX · Virtus Equity Trust
2.12%of fund net assets
T. Rowe Price Small-Cap Value Fund, Inc.
PRSVX · T. ROWE PRICE SMALL-CAP VALUE FUND, INC.
0.11%of fund net assets
0.39%of fund net assets

Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.

Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.

Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.

Connected research

Put this business in context.

Compare this company with peers, find it in your funds and follow its financial history with your connected AI:

  • “How do IRADIMED CORP and its peers compare on margins and cash generation over ten years?”
  • “Where did five years of IRADIMED CORP's earnings go — cash, debt, buybacks, reinvestment?”
  • “What changed in IRADIMED CORP's last four quarterly filings that the numbers alone won't show?”
See how it works →All research tools with a subscription. Use your own AI account.